AFAM
Almost Family IncNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Dec. 7, 7:29 AM
    • Almost Family (NASDAQ:AFAM) announces that it has entered into a new five-year $350M revolving credit facility that increases its financial flexibility through 2021. It replaces its previous $175M credit facility.  The new facility includes an accordion feature which permits expansion up to $500M.
    • The Company also announced that it cleared the necessary regulatory approvals to acquire a controlling interest in the entity holding the home health and hospice assets of Community Health Systems (NYSE:CYH). The Company expects to fund the acquisition on December 30.
    | Wed, Dec. 7, 7:29 AM
  • Fri, Nov. 4, 8:16 AM
    • Almost Family (NASDAQ:AFAM) upgraded to Outperform from Neutral by Baird. Price target raised to $55 (35% upside) from $44.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Outperform from Market Perform by BMO Capital. Price target lowered to $84 (17% upside) from $98.
    • Dentsply Sirona (NASDAQ:XRAY) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $69 (16% upside) from $65.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Strong Buy from Buy by Needham. Price target lowered to $148 (44% upside) from $150.
    • Stryker (NYSE:SYK) upgraded to Market Perform from Underperform with a $125 (8% upside) price target by BMO Capital.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Neutral by Credit Suisse. Price target lowered to $52 (33% upside) from $59.
    • Cempra (NASDAQ:CEMP) downgraded to Hold from Buy by Stifel Nicolaus. Price target lowered to $8 (6% upside) from $37. Downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $6 (21% downside risk) from $25. Downgraded to Underperform from Outperform by Baird. Price target lowered to $6 (21% downside risk) from $33.
    • Diplomat Pharmacy (NYSE:DPLO) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $18 (39% upside) from $35. Downgraded to Market Perform by Citigroup and Avondale Partners.
    • WebMD (NASDAQ:WBMD) downgraded to Neutral from Buy by Mizuho Securities. Price target lowered to $52 (5% upside) from $63.
    • Pfizer (NYSE:PFE) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $33 (10% upside) from $40. Downgraded to Hold from Buy by Argus.
    • Adeptus Health (NYSE:ADPT) downgraded to Underperform from Buy by Bank of America. Downgraded to Hold from Buy by Jefferies. Price target lowered to $13 (48% upside) from $77.
    • Sangamo BioSciences (NASDAQ:SGMO) downgraded to Neutral from Overweight by Wedbush and Piper Jaffray. Price targets lowered to $4 (25% upside) from $30 and $5 (56% upside) from $9, respectively.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Buy by Citigroup and to Hold from Buy by DNB Markets.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $60 (7% upside) from $70.
    | Fri, Nov. 4, 8:16 AM | 18 Comments
  • Tue, Nov. 1, 6:03 PM
    • Almost Family (NASDAQ:AFAM): Q3 EPS of $0.66 beats by $0.07.
    • Revenue of $160.4M (+22.2% Y/Y) beats by $1.23M.
    • Press Release
    | Tue, Nov. 1, 6:03 PM | 1 Comment
  • Fri, Oct. 21, 7:46 AM
    • Almost Family (NASDAQ:AFAM) upgraded to Outperform from Sector Perform with a $55 (31% upside) price target by RBC Capital.
    • Walgreens Boots Alliance (NASDAQ:WBA) upgraded to Buy from Hold by Jefferies. Price target raised to $95 (17% upside) from $87.
    • Arbutus Biopharma (NASDAQ:ABUS) upgraded to Neutral from Sell with a $3 price (0% upside) target by Chardan Capital.
    • Quintiles IMS Holdings (NYSE:Q) downgraded to Hold from Buy with a $79 (6% upside) price target by Jefferies.
    • Anthem (NYSE:ANTM) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $132 (6% upside) from $154.
    • Bluebird bio (NASDAQ:BLUE) downgraded to Sell from Hold by Cantor Fitzgerald. Price target lowered to $37 (32% downside risk) from $42.
    • Henry Schein (NASDAQ:HSIC) downgraded to Neutral from Buy by Baird. Price target lowered to $164 (7% upside) from $176.
    | Fri, Oct. 21, 7:46 AM
  • Tue, Oct. 18, 10:24 AM
    • Almost Family's (NASDAQ:AFAM) acquisition of Community Health's (NYSE:CYH) home health assets is "very accretive" and not adequately reflected in its shares, Jefferies analyst Brian Tanquilut says.
    • The deal underscores Almost Family's low valuation. Tanquilut says AFAM is "meaningfully undervalued." Maintains Buy rating and $58 price target. Implied upside 44.5%.
    • AFAM is up another 3.6% today to $40.15.
    | Tue, Oct. 18, 10:24 AM
  • Mon, Oct. 17, 11:56 AM
    • Thinly traded micro cap Almost Family (AFAM +8.3%) heads north on modestly higher volume in response to its announcement that it has inked a deal with Community Health Systems (CYH -0.3%) for a controlling interest in CHS Home Health, comprised of 74 home health and 15 hospice branch locations in 22 states. CYH's home health and hospice businesses generate $170M and $30M, respectively, in annual revenues. The transaction increases the number of AFAM branches to 340 with an annualized revenue run rate of more than $800M. It will be accretive to EPS in 2017.
    • Under the terms of the agreement, AFAM will acquire an 80% interest in CHS Home Health for $128M, subject to a working capital adjustment. The transaction should be completed this quarter.
    | Mon, Oct. 17, 11:56 AM | 3 Comments
  • Wed, Aug. 3, 7:35 AM
    • Almost Family (NASDAQ:AFAM): Q2 EPS of $0.61 misses by $0.03.
    • Revenue of $156M (+22.5% Y/Y) beats by $0.81M.
    • Press Release
    | Wed, Aug. 3, 7:35 AM
  • Tue, Aug. 2, 5:30 PM
  • Wed, May 4, 7:36 AM
    • Almost Family (NASDAQ:AFAM): Q1 EPS of $0.53 misses by $0.05.
    • Revenue of $153.7M (+19.7% Y/Y) beats by $0.2M.
    | Wed, May 4, 7:36 AM
  • Tue, May 3, 5:30 PM
  • Wed, Mar. 2, 8:38 AM
    • Almost Family (AFAM) Q4 results: Revenues: $145.2M (+16.3%); G&A: $62M (+23.0%); Operating Income: $5.5M (-31.3%); Net Income: $2.8M (-40.4%); EPS: $0.28 (-44.0%); Non-GAAP EPS: $0.62 (+29.2%).
    • FY2015 results: Revenues: $532.2M (+7.3%); G&A: $218.3M (+5.3%); Operating Income: $32.1M (+31.0%); Net Income: $20M (+44.9%); EPS: $2.05 (+41.4%); Non-GAAP EPS: $2.20 (+22.9%); Quick Assets: $7.5M (+8.7%).
    • No guidance given.
    | Wed, Mar. 2, 8:38 AM
  • Wed, Mar. 2, 7:33 AM
    • Almost Family (NASDAQ:AFAM): Q4 EPS of $0.62 beats by $0.07.
    • Revenue of $145.22M (+16.4% Y/Y) misses by $3.79M.
    | Wed, Mar. 2, 7:33 AM
  • Tue, Mar. 1, 5:30 PM
  • Nov. 4, 2015, 9:19 AM
    • Almost Family (NASDAQ:AFAM): Q2 EPS of $0.52 in-line.
    • Revenue of $129.18M (+4.4% Y/Y) misses by $3.96M.
    | Nov. 4, 2015, 9:19 AM
  • Nov. 3, 2015, 5:30 PM
  • Aug. 26, 2015, 11:42 AM
    • Home healthcare company Amedisys (NASDAQ:AMED) has significantly amped up its acquisition ambitions, putting together a lengthy list of possible targets as it looks to consolidate a fragmented industry.
    • New CEO Paul Kusserow says the company is looking at more than 200 candidates for outright M&A as well as joint ventures and partnerships: "We have a lot of firepower, a lot of powder, to go out and buy things on a large scale."
    • That's up from 15 prospects in its deal pipeline just six months ago.
    • Changes to how the government pays for home healthcare for Medicare patients stands to benefit Amedisys, as weaker performers are driven out, Kusserow says: "There is going to be tremendous consolidation in this industry if these things come close to fruition."
    • Amedisys is one of the larger players in the sector, along with Kindred Healthcare (NYSE:KND), Almost Family (NASDAQ:AFAM) and LHC Group (NASDAQ:LHCG).
    | Aug. 26, 2015, 11:42 AM